Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets

Publication date: Available online 11 September 2018

Source: Autoimmunity Reviews

Author(s): Irene Cecchi, Ivan Arias de la Rosa, Elisa Menegatti, Dario Roccatello, Eduardo Collantes-Estevez, Chary Lopez-Pedrera, Nuria Barbarroja

Abstract

Rheumatoid Arthritis (RA) is a complex systemic autoimmune disease in which various cell types are involved. Among them, neutrophils have been recognized as important players in the onset and the progression of RA. The pathogenic role of neutrophils in RA lies in the alteration of several processes, including increased cell survival and migratory capacity, abnormal inflammatory activity, elevated oxidative stress and an exacerbated release of neutrophil extracellular traps. Through these mechanisms, neutrophils can activate other immune cells, thus perpetuating inflammation and leading to the destruction of the cartilage and bone of the affected joint.

Given the considerable contribution of neutrophils to the pathophysiology of RA, several studies have attempted to clarify the effects of various therapeutic agents on this subtype of leukocyte.

To date, recent studies have envisaged the role of new molecules on the pathogenic profile of neutrophils in RA, which could represent novel targets in future therapies.

In this review, we aim to review the pathogenic role of neutrophils in RA, the effect of conventional treatments and biologic therapies, and the new, potential targets of neutrophil-derived molecules for the treatment of RA.

https://ift.tt/2MnprI6